Inventor
TARSI LUCA
IT16 patents
⚠️ This page may combine multiple inventors who share the name “TARSI LUCA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
INDIVIOR UK LTD
6 patentsUS10000477B2Jun 19, 2018
Dopamine D3 receptor antagonist compounds
INDIVIOR UK LTD2 citations70
US10239870B2Mar 26, 2019
Dopamine D3 receptor antagonists
INDIVIOR UK LTD1 citations67
US10273244B2Apr 30, 2019
Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators
INDIVIOR UK LTD1 citations59
US10654842B2May 19, 2020
Dopamine D3 receptor antagonist compounds
INDIVIOR UK LTD0 citations49
US10584135B2Mar 10, 2020
Substituted 3,6-diazabicyclo[3.2.0]heptanes
INDIVIOR UK LTD0 citations49
US10577361B2Mar 3, 2020
Dopamine D3 receptor antagonists having a morpholine moiety
INDIVIOR UK LTD0 citations34
GLAXO GROUP LTD
5 patentsUS7855298B2Dec 21, 2010
Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine D3 receptors
GLAXO GROUP LTD11 citations82
US7799815B2Sep 21, 2010
Triazole derivatives as modulators of dopamine D3 receptors
GLAXO GROUP LTD7 citations72
US8003638B2Aug 23, 2011
7-pyrazolylbenzazepines having affinity for D3 receptor
GLAXO GROUP LTD0 citations51
US8030322B2Oct 4, 2011
Spirocompounds useful as modulators for dopamine D3 receptors
GLAXO GROUP LTD0 citations40
US7989444B2Aug 2, 2011
Compounds having affinity for dopamine D3 receptor and uses thereof
GLAXO GROUP LTD0 citations39
CHRONOS THERAPEUTICS LTD
2 patentsUS11660293B2May 30, 2023
Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
CHRONOS THERAPEUTICS LTD0 citations47
US9920053B2Mar 20, 2018
N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system
CHRONOS THERAPEUTICS LTD0 citations31